Related Topics News -

     
 Title only   |   Print 
     
《大行》中金列出內地主動偏股型基金第二季按季增幅最多重倉港股(表)

2025-07-24T  
《大行》中金:內地公募基金上季增持生物醫藥、內銀及內險 個股信達生物、三生製藥與泡泡瑪特增持最多

2025-07-24T  
《大行》美銀證券:內地生物製藥股銷售表現穩健 升百濟神州目標價至205.31元

2025-07-23T  
《大行》摩通:今年中國醫療保健行業顯著反彈 看好康方生物信達生物及恆瑞醫藥

2025-07-18T  
《大行》里昂升信達生物目標價至108.4元 維持「跑贏大市」評級

2025-07-11T  
《大行》招銀國際建議理性看待創新藥估值

2025-07-09T  
《大行》里昂升信達生物目標價至108.4元 聚焦下一代腫瘤產品線

2025-07-08T  
《大行》建銀國際升信達生物目標至100元 維持「跑贏大市」

2025-07-08T  
《大行》匯豐研究升信達生物目標價至110元 維持「買入」評級

2025-07-08T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.